Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | — |
The patient did not take the remaining doses of Vivotif every other day; Case reference number US-BN-2025-002012 is a spontaneous case initially received from a consumer via Bavarian Nordic (reference number: CASE-001366) on 26-Dec-2025 and concerns a male patient of an unknown age. The patient's medical history and concomitant medications details were provided. On 15-Dec-2025, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, route and site of administration for an unknown indication. On an unspecified date, the patient took an unspecified number of doses of Vivotif (batch number: unknown) at an unknown dose, route and site of administration. As reported, the patient did not take the remaining doses of Vivotif every other day (explicitly coded as 'inappropriate schedule of vaccine administration'). At the time of initial report, it was unknown if the patient experienced any adverse event due to vaccination with Vivotif. No further information was provided.; Reporter's Comments: A male patient of an unknown age did not take the remaining doses of Vivotif every other day, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to vaccination with Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications details were provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of an unknown age did not take the remaining doses of Vivotif every other day, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to vaccination with Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications details were provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.